Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
Alcohol Use Disorder, Cannabis Use Disorder
About this trial
This is an interventional treatment trial for Alcohol Use Disorder
Eligibility Criteria
Inclusion Criteria: Patient has been referred to and intends to participate in either the AUD or CUD Integrated Care Pathway (and is therefore willing to participate in group psychotherapy). Able to communicate and provide informed consent in English. 18 years of age or older. Willing and able to safely abstain from substances (other than nicotine or tobacco products), including alcohol and cannabis, for 12 hours prior to the eligibility and task-based assessments. Meets DSM-5 diagnostic criteria for AUD (AUD group) or CUD (CUD group) Meets criteria for risky drinking, defined as > 10 drinks per week for females and > 15 drinks per week for males on average over the past 30 days (AUD group) or daily or near-daily cannabis use over the past 30 days, defined as ≥ 4 days of cannabis use per week on average (CUD group) Exclusion Criteria: Active suicidal ideation at time of assessment. Suicide attempt within the past month. Unstable psychiatric or medical status (e.g., acute psychosis or mania) or unstable use of another substance that may interfere with participation in groups (e.g. active fentanyl use). Enrollment in another study that conflicts with the procedures or scientific integrity of this study. Individuals planning to be out of the province for a substantial amount of time during the treatment period will not be permitted to enroll.
Sites / Locations
- Centre for Addiction and Mental HealthRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
AUD
CUD
Participants will be treated with 12 weeks of CBT for AUD (group therapy) and have the option to receive evidence-based pharmacotherapy for AUD guided by a pharmacotherapy algorithm.
Participants will be treated with 12 weeks of CBT + motivational enhancement therapy for CUD (group therapy).